米CDCがスポンサーの論文 新型コロナ後遺症の存在を証明できず。LoL

July 24, 2024

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection
Elizabeth R. Unger, MD, PhD1; Jin-Mann S. Lin, PhD1; Lauren E. Wisk, PhD2; et alHuihui Yu, PhD3; Michelle L’Hommedieu, PhD2; Helen Lavretsky, MD, MS4; Juan Carlos C. Montoy, MD, PhD5; Michael A. Gottlieb, MD6; Kristin L. Rising, MD, MSHP7,8; Nicole L. Gentile, MD, PhD9,10,11; Michelle Santangelo, MS12; Arjun K. Venkatesh, MD, MBA, MHS3,13; Robert M. Rodriguez, MD5; Mandy J. Hill, DrPH, MPH14; Rachel E. Geyer, MPH10; Efrat R. Kean, MD7; Sharon Saydah, PhD15; Samuel A. McDonald, MD, MS16,17; Ryan Huebinger, MD14; Ahamed H. Idris, MD16; Jocelyn Dorney, MPH3; Bala Hota, MD, MPH18; Erica S. Spatz, MD, MHS3,19; Kari A. Stephens, PhD10,20; Robert A. Weinstein, MD12,21; Joann G. Elmore, MD, MPH2; for the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) Group
Author Affiliations Article Information
JAMA Netw Open. 2024;7(7):e2423555. doi:10.1001/jamanetworkopen.2024.23555

Question Does prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)–like illness differ between individuals with an acute infection–like index illness who are COVID-19 positive or negative?

Findings In this cohort study of 4378 participants, the weighted prevalence of ME/CFS-like illness was 4.5% or less at 3 to 12 months after the index illness in the COVID-19–positive and COVID-19–negative groups, with no significant differences in odds of ME/CFS-like illness.

Meaning The findings suggest that ME/CFS-like illness following an acute infection–like index illness does not vary by COVID-19 test result.
Abstract
Importance Chronic symptoms reported following an infection with SARS-CoV-2, such as cognitive problems, overlap with symptoms included in the definition of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Objective To evaluate the prevalence of ME/CFS-like illness subsequent to acute SARS-CoV-2 infection, changes in ME/CFS symptoms through 12 months of follow-up, and the association of ME/CFS symptoms with SARS-CoV-2 test results at the acute infection–like index illness.

Design, Setting, and Participants This prospective, multisite, longitudinal cohort study (Innovative Support for Patients with SARS-CoV-2 Infections Registry [INSPIRE]) enrolled participants from December 11, 2020, to August 29, 2022. Participants were adults aged 18 to 64 years with acute symptoms suggestive of SARS-CoV-2 infection who received a US Food and Drug Administration–approved SARS-CoV-2 test at the time of illness and did not die or withdraw from the study by 3 months. Follow-up surveys were collected through February 28, 2023.

Exposure COVID-19 status (positive vs negative) at enrollment.

Main Outcome and Measures The main outcome was the weighted proportion of participants with ME/CFS-like illness based on the 2015 Institute of Medicine clinical case definition using self-reported symptoms.

Results A total of 4378 participants were included in the study. Most were female (3226 [68.1%]). Mean (SD) age was 37.8 (11.8) years. The survey completion rates ranged from 38.7% (3613 of 4738 participants) to 76.3% (1835 of 4738) and decreased over time. The weighted proportion of participants identified with ME/CFS-like illness did not change significantly at 3 through 12 months of follow-up and was similar in the COVID-19–positive (range, 2.8%-3.7%) and COVID-19–negative (range, 3.1%-4.5%) groups. Adjusted analyses revealed no significant difference in the odds of ME/CFS-like illness at any time point between COVID-19–positive and COVID-19–negative individuals (marginal odds ratio range, 0.84 [95% CI, 0.42-1.67] to 1.18 [95% CI, 0.55-2.51]).

Conclusions and Relevance In this prospective cohort study, there was no evidence that the proportion of participants with ME/CFS-like illness differed between those infected with SARS-CoV-2 vs those without SARS-CoV-2 infection up to 12 months after infection. A 3% to 4% prevalence of ME/CFS-like illness after an acute infection–like index illness would impose a high societal burden given the millions of persons infected with SARS-CoV-2.


https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2821459

要するに…

新型コロナウイルスに感染したことがあろうがなかろうが、「患者が慢性疲労症候群のような症状を発症する確率に大差無し」。

 で、新型コロナワクチン接種者と未接種者を比較した場合はどうかな？

Long Covid cannot be blamed for constant tiredness, brain fog or muscle pain, study suggestsREAD MORE: Scientists pinpoint why women are more at risk of long Covid
By EMILY JOSHU HEALTH REPORTER FOR DAILYMAIL.COM
PUBLISHED: 11:26 EDT, 24 July 2024 | UPDATED: 11:42 EDT, 24 July 2024

Constant tiredness. Brain fog. Muscle pain.

These are the most common complaints by people with 'long Covid'.

But a new study suggests these symptoms are just as likely to occur in people who never caught Covid.

After following thousands of people who had and had not tested positive, the team found Covid made 'no difference' in whether or not someone would go on to develop those issues - fatigue, problems with thinking or memory, and muscle pain.

The study, dubbed INSPIRE and funded by the CDC, is part of a growing body of research suggesting that long Covid symptoms could be overblown or attributed to other illnesses.


Long Covid also been thrust back into the spotlight recently, as Ben Affleck and Jennifer Garner's daughter Violet Affleck argued in favor of mask mandates.

The 18-year-old claims she contracted a 'post-viral infection' in 2019.

Researchers at the University of California - Los Angeles (UCLA) recruited more than 4,000 adults who tested positive for Covid between December 2020 and August 2022.

The participants were divided into two groups: Covid-positive and Covid-negative.

Among both groups, three to four percent of participants reported symptoms consistent with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - a disease that causes extreme fatigue, brain fog, and similar symptoms.

This finding suggests that Covid made 'no difference' in whether or not someone would develop the illness, even though Covid has long been considered a cause of ME/CFS.

Dr Joann Elmore, co-senior author of the study and professor of internal medicine and health services research at UCLA, said: 'ME/CFS is no more likely to occur in people infected with COVID-19 than people with other acute illnesses.'

However, the prevalence of ME/CFS 'could impose a very high burden on society and our healthcare system,' she said.

One major caveat though is that ME/CFS is difficult to diagnose, as there is no gold-standard test to find the disease. This means that symptoms like exhaustion could be due to other illnesses.

The researchers recruited 4,378 participants ages 18 to 64 who tested positive for Covid between December 2020 and August 2022 and were symptomatic.

Patients older than 65 were excluded to rule out 'age-related' illnesses that could contribute to ME/CFS.

The average participant age was 38, and about 68 percent of patients were female.

At each three-month follow-up, approximately one-third of participants in both groups reported at least one of the following five symptoms: postexertional malaise (feeling tired after minimal physical or mental activity), unrefreshing sleep, fatigue, orthostatic intolerance (difficulty standing or sitting upright), and cognitive impairment.

This suggests that patients who did and did not have Covid had a similar symptom presentation.

Unrefreshing sleep was the most common symptom in both groups.

'Our findings suggest that COVID-19 is no more likely than other acute infections to be associated with ME/CFS and that acute illnesses more broadly may be associated with chronic symptom burden from ME/CFS,' the researchers wrote.

There were several limitations to the research, including the possibility of false-positive test results and symptoms being self-reported.

However, the research adds to a growing body of evidence suggesting that long Covid could be overblown or debunked.

One major study from researchers in the US, UK, and Denmark claimed that the risks of long Covid have been 'greatly exaggerated' and that the condition is too 'broadly defined.'

Other experts have argued that the condition is 'indistinguishable' from other post-viral illnesses.

The new study was published Wednesday in JAMA Network Open.

https://www.dailymail.co.uk/health/article-13667963/long-covid-symptom-debunked-study-ucla-cdc.html

LoLLoLLoLLoLLoLLoLLoL

LoLLoLLoLLoLLoLLoLLoL

LoLLoLLoLLoL